RudaCure, which is developing 疼痛治疗药s, has today completed the 专利 filing for its invention of peptides with TRPV1 inhibitory activity.
Combined with AI-based drug screening and traditional in vitro and in vivo methods, RudaCure has secured a group of active peptides. This is a substance 专利 and use 专利 filing for materials that demonstrate 疗效 and 副作用 suppression in various pain 动物模型.
Negotiations are underway with a domestic company for 联合研究 on these materials, and discussions are also in progress with multinational 制药公司. These compounds are expected to emerge as a new option in the pain market, where there is high demand for non-addictive, side-effect-free drugs.
